An observational study in Metabolic Dysfunction-associated Steatotic Liver Disease, sponsored by Fundacion de Investigacion Science and Education. Recruiting at 1 site in Puerto Rico. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-10.
Sponsored by Fundacion de Investigacion Science and Education · Observational
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of liver disease worldwide. The condition is defined by fat accumulation exceeding 5% of liver weight not explained by at-risk alcohol intake. Risk factors include obesity, diabetes, genetic variants, dietary factors, and gut microbiota alterations. However, the interdependence of these factors and their individual impact on disease severity remain unclear. The investigators aim to investigate the changes in the gut microbiome of Hispanics living in Puerto Rico with MASLD associated with wild-type and mutated genotype status of PNPLA3 rs738409, a strong genetic contributor to MASLD. In this cross-sectional study, blood and fecal samples will be collected from participants who have completed a non-invasive transient elastography test (FibroScan) to measure the extent of hepatic steatosis (fat in the liver). Genotyping for the PNPLA3 rs738409 variant will be conducted. Fecal samples will be collected to analyze the V4 region of the 16S rRNA gene for intestinal microbiota characterization. Alpha and beta diversity analysis will be measured by MASLD status and PNPLA3 genotype to evaluate biodiversity within and between samples.
The liver is the powerhouse of the body, overseeing many functions such as the production of clotting factors, sugars, fats, and the metabolism of drugs. MASLD is the most common chronic liver disease worldwide, affecting one in three adults and one in ten children. MASLD, more commonly referred to as "fatty liver," can lead to fat accumulation in liver cells or steatosis and is strongly associated with obesity and diabetes. The disease is usually considered a silent condition with few symptoms until advanced liver disease or cirrhosis develops. Fortunately, fatty liver may be reversed by adopting a healthy lifestyle, including weight loss and exercise. However, the pathogenesis of MASLD remains incompletely understood, and the Hispanic subpopulation is affected the most.
A multi-hit model has been proposed that most accurately describes both the development of simple steatosis and its transition from simple steatosis to progressive stages of the disease. In this model, a close interaction between dietary, environmental, and genetic factors with insulin resistance, lipotoxicity, and fat metabolism comprises multiple insults acting together on predisposed subjects to induce MASLD. This model has led to the understanding that the interplay between diet, genetics, and gut microbiota is of utmost importance in the development and progression of the condition. As a multi-factorial disease, assigning specific disease pathways to the overall phenotype has been challenging. Still, it is important to investigate associations between its risk factors to direct therapeutic interventions to the most relevant pathways.
Looking at two of the most relevant risk factors, this study aims to investigate whether there are any differences in the taxonomic composition of the gut microbiota between Hispanic patients with MASLD with different PNPLA3 genotypes. The PNPLA3 (patatin-like phospholipase domain-containing protein 3) polymorphism has been implicated in the pathogenesis and progression of the condition. However, the role of PNPLA3 polymorphism in shaping the fecal microbiota composition in Hispanic patients with MASLD remains unclear. Once fecal and blood samples are collected from a cohort of Hispanic individuals with MASLD, fecal microbiota sequencing and PNPLA3 genotyping will be done. Findings will reveal whether there are significant alterations in the fecal microbiota composition in relation to PNPLA3 polymorphism in Hispanic patients with MASLD. Results could provide evidence for a potential link between PNPLA3 polymorphism and fecal microbiota composition in Hispanic individuals with MASLD.
2,083 studies on the registry are indexed under Liver Diseases; 392 are open to participants now.
This study's planned enrollment of 100 is below the median of 167 across 683 observational studies indexed under Liver Diseases.
Browse Liver Diseases studies →This is the only study on the registry with Fundacion de Investigacion Science and Education as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The aim of this study is to determine the changes in the gut microbiome in Hispanics living in Puerto Rico with MASLD associated to wild-type and mutated PNPLA3 genotype status will also be assessed in this study population. To maintain homogeneity of the study population and to achieve the study objectives, the study will only be including individuals who self-identify as Hispanic and currently reside in Puerto Rico. Exclusion of non-Hispanic individuals is necessary to ensure that obtained results are representative of the Hispanic population in Puerto Rico and can be generalized to this population.
A subject must meet the following criteria to be eligible for inclusion in the study:
Patient must be of Hispanic ethnicity residing in Puerto Rico. Age 21 to 75 years old at time of informed consent. Evidence of MASLD by vibration-controlled transient elastography (FibroScan) controlled attenuation parameter (CAP) (value must be greater than or equal to 248 dB/m).
Willing and able to provide informed consent signed by study subject. Willing and able to understand and complete study-related procedures.
Exclusion Criteria:
A subject who meets any of the following criteria will be excluded from the study:
Excessive alcohol intake for ≥3 months during past year prior to screening (>3 units/day for males and >2 units/day for female is generally considered excessive).
History of liver transplant, or current placement on a liver transplant list. History of viral and resolved hepatitis (Hepatitis B or C) or human immunodeficiency virus (HIV).
Use of antibiotics within 14 days of screening.
Microbiota characterization
To determine the changes in the gut microbiome of Hispanics living in Puerto Rico with MASLD associated to wild-type and mutated genotype status of PNPLA3 rs738409, a strong genetic contributor to MASLD.
Time frame: 1 year
Microbiota diversity based on eating patterns
To determine microbiome diversity in Hispanics with different eating patterns.
Time frame: 1 year
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.